ioresorbable scaffolds (BRS) have been one of the latest revolutions in interventional cardiology. Because of their reabsorptive properties, they provide temporary scaffolding that promotes vessel healing and then disappear, thus restoring a functional endothelium and vasomotion. Although several BRS platforms have been developed, real-world experience is mostly limited to Absorb (Abbott Vascular, Santa Clara, CA), which has demonstrated comparable 1-year outcomes with a metallic everolimus-eluting stent (Xience; Abbott Vascular) in 4 large randomized trials. [1] [2] [3] [4] The reabsorptive properties of BRS make them particularly appealing when long segments of coronary arteries Background-There is little evidence regarding the efficacy and safety of bioresorbable scaffolds (BRS) for the percutaneous treatment of chronic total occlusions. Methods and Results-We performed a multicenter registry of consecutive chronic total occlusion patients treated with BRS (Absorb; Abbott Vascular) and second-generation drug-eluting stents (DES) at 5 institutions. Long-term targetvessel failure (a composite of cardiac death, target-vessel myocardial infarction, and ischemia-driven target-lesion revascularization) was the primary end point. Inverse probability of treatment weight-adjusted Cox regression was used to account for pretreatment differences between the 2 groups. A total of 537 patients (n=153 BRS; n=384 DES) were included. BRS patients were younger and had lower prevalence of comorbidities. Overall mean Japan-Chronic Total Occlusion (J-CTO) score was 1.43±1.16, with no differences between groups. Procedural success was achieved in 99.3% and 96.6% of BRS-and DES-treated patients, respectively (P=0.07). At a median follow-up of 703 days, there were no differences in target-vessel failure between BRS and DES (4.6% versus 7.7%; P=0.21). By adjusted Cox regression analysis, there were still no significant differences between BRS and DES (hazard ratio, 1.54; 95% confidence interval, 0.69-3.72; P=0.34). However, secondary analyses suggested a signal toward higher ischemiadriven target-lesion revascularization with BRS. Conclusions-Implantation of BRS versus second-generation DES in chronic total occlusion was associated with similar risk of target-vessel failure at long-term follow-up. However, a signal toward increased ischemia-driven target-lesion revascularization with BRS was observed. Large randomized studies should confirm these findings. (Circ Cardiovasc Interv. 2016;9:e004284.
BRS vs DES for CTO PCI
need to be stented, such as in chronic total occlusion (CTO) percutaneous coronary intervention (PCI). However, CTO lesions were excluded in all BRS trials, and available evidence derives from small single-center, single-arm studies of Absorb. [5] [6] [7] [8] Our study aim was to compare the procedural and long-term clinical outcomes of Absorb versus second-generation drug-eluting stents (DES) in a multicenter registry of CTO patients.
Methods

Patient Population
We queried the databases of the 5 participating centers to identify all consecutive patients who underwent CTO PCI with successful wire crossing of the occlusion followed by either BRS or DES implantation. Procedures were performed by experienced CTO PCI operators (>80% success rate 9 ) between January 2012 and December 2015. Baseline, procedural, and hospitalization data were recorded. Followup was performed by means of phone interview, review of hospital records, or outpatient visit. The study was approved by the institutional review board of the participating centers, and study subjects gave their informed consent.
Study Devices and Implantation Technique
The only BRS used in this study was Absorb. However, several second-generation DES were used: Xience Prime, Xience Xpedition, and Xience Pro X (Abbott Vascular); Promus Premier, Promus Element and Synergy (Boston Scientific, Marlborough, MA); Resolute Integrity and Resolute Onyx (Medtronic, Minneapolis, MN); Nobori and Ultimaster (Terumo, Tokyo, Japan); BioMatrix (Biosensors International, Singapore); Combo (OrbusNeich, Hong Kong); Xposition S (Stentys, Paris, France); and Cre8 (Alvimedica, Istanbul, Turkey).
BRS implantation was performed as recommended by expert consensus (aggressive lesion preparation, appropriate sizing, routine intravascular imaging guidance, and high-pressure postdilatation with noncompliant balloons with a balloon-to-artery ratio of ≈1).
10 DES implantation technique was left at the operator discretion. Figures 1  and 2 show examples of CTO PCI with BRS and DES, respectively.
Definitions
CTO was defined as a 100% stenosis with antegrade Thrombolysis In Myocardial Infarction 0 flow for >3 months. The Japan-Chronic Total Occlusion (J-CTO) score was calculated, and quantitative coronary analysis was performed for each lesion. Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score and residual SYNTAX score were calculated at baseline and postprocedure, respectively.
Technical success was defined as a residual stenosis <30% with Thrombolysis In Myocardial Infarction 3 flow in the CTO vessel. 11 Procedural success was defined as technical success plus the absence of in-hospital all-cause death, periprocedural myocardial infarction (elevation of creatine kinase, muscle and brain subunit to >5× upper limit of normal within 48 hours), stroke, recurrent angina requiring target-vessel revascularization with PCI or coronary artery bypass graft, tamponade requiring pericardiocentesis, or surgery. 11 Procedural complications included vascular complications, major bleeding (bleeding requiring transfusion, vasopressors, surgery, or percutaneous intervention), coronary perforation, and contrast-induced nephropathy (increase in serum creatinine >25% or >0.5 mg/dL at 48 hours postprocedure).
The primary end point was the incidence of target-vessel failure (TVF) on follow-up, defined as the composite of cardiac death, target-vessel myocardial infarction (elevation of troponin or creatine kinase, muscle and brain subunit >upper limit of normal, plus 1 or more of the following: (1) symptoms of ischemia; (2) ECG changes indicative of new ischemia [new ST-T changes or new left bundle branch block]; (3) development of pathological Q-waves; (4) imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality), and ischemia-driven target-lesion revascularization (ID-TLR).
2 Definite or probable stent thrombosis was adjudicated according to the Academic Research Consortium definitions.
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Statistical Analysis
Statistical analyses were performed by an independent researcher (G.G.). Continuous variables are presented as mean±SD and compared with Student t test. Categorical variables are presented as frequency (percentages) and compared using the χ 2 test. Unadjusted curves of survival free from TVF and ID-TLR were generated with the Kaplan-Meier method and compared with the log-rank test.
To account for selection bias between BRS-and DES-treated patients, propensity score adjustment by means of inverse probability of treatment weight (IPTW) was performed. 13, 14 The propensity score was estimated with multivariable logistic regression for BRS treatment probability including pretreatment clinical and angiographic variables potentially associated with BRS and the primary end point. The following covariates were included in the propensity score: age, sex, diabetes mellitus, previous PCI, previous coronary artery bypass graft, previous myocardial infarction, chronic kidney disease, peripheral artery disease, left ventricular ejection fraction, SYNTAX score, reference vessel diameter (RVD), indication to CTO PCI, CTO localization, and J-CTO score. Goodness of fit of the propensity score was evaluated with the Hosmer-Lemeshow test. The distribution of propensity scores for the entire cohort and within each treatment group was visually examined with the kernel density plot. The weight for BRS treatment was the inverse of the propensity score, whereas the weight for DES treatment was the inverse of 1−propensity score. Baseline and post-IPTW adjustment balance between covariates were assessed by means of standardized mean differences. Variables were considered as balanced if the standardized mean difference was <10%. 13 Cox regression models were weighted using IPTW and stratified by center to account for potential between-center
WHAT IS KNOWN
• The reabsorptive properties of bioresorbable scaffolds (BRS) make them particularly appealing when long segments of coronary arteries need to be stented, such as in chronic total occlusions.
• Small single-center single-arm registries have suggested the technical feasibility of BRS implantation in chronic total occlusions, although comparisons with drug-eluting stent-treated cohorts are lacking.
WHAT THE STUDY ADDS
• BRS implantation in chronic total occlusions has a high success rate, with low incidence of complications and acceptable clinical outcomes at long-term follow-up.
• The primary end point of target-vessel failure was comparable between BRS-and drug-eluting stenttreated subjects.
• In a secondary analysis, BRS showed a signal toward a higher risk of ischemia-driven target-lesion revascularization compared with drug-eluting stent; however, this finding should be regarded as hypothesis-generating only, and randomized controlled trials are needed to shed further light on the role of BRS in chronic total occlusions percutaneous coronary intervention.
heterogeneity. The proportionality assumption was verified using the Schoenfeld residuals method. Adjusted Kaplan-Meier survival curves were generated by weighting the survival function with the IPTW in the 2 groups. In a secondary analysis (doubly robust IPTW adjustment 15 ), the Cox regression models were sequentially augmented with clinical, angiographic, and procedural confounders that either remained unbalanced after the initial IPTW adjustment (standardized mean difference >10%) or were deemed to be Figure 1 . A, Bioresorbable scaffolds (BRS) implantation in a 55-year-old man with mid-left anterior descending chronic total occlusion. B, The lesion was crossed antegradely, using with a Gaia Second (Asahi Intecc, Nagoya, Japan) on a FineCross (Terumo, Tokyo, Japan). C, Aggressive lesion predilatation was performed with 2.5-and 3.0-mm noncompliant balloons. D, Optimal final result confirmed by intravascular ultrasound, after implantation of 2 overlapping Absorb BRS, which were postdilated at high pressure with 2.5-mm and 3.0-mm noncompliant balloons. Figure 2 . A, Drug-eluting stent (DES) implantation in a 66-year-old man with mid-left anterior descending chronic total occlusion. B, The lesion was crossed antegradely, using with a Gaia Third (Asahi Intecc) on a Corsair (Asahi Intecc). C, Aggressive lesion predilatation was performed with a 2.5-mm noncompliant balloon, which, however, could not expand properly because of extensive calcification (arrow). Rotational atherectomy was then performed and further predilatation followed. D, Optimal final result, after implantation of 2 overlapping DES and high-pressure postdilatation with a 3.0-mm noncompliant balloon.
associated with the outcomes of interest (TVF and ID-TLR), using a ratio of 1:8 covariates-to-number-of-events in the IPTW population to avoid overfitting.
To assess the robustness of the results, sensitivity analyses were performed. First, to account for outlier effect within the propensity score, IPTW-adjusted analyses were repeated using trimming technique by excluding observations with propensity score above the 95th percentile and below the 5th percentile. Second, to account for center-specific effect, the analysis for the primary end point was repeated with sequential exclusion of each center and measuring the interaction between treatment device and center in the Cox model. All tests were 2-tailed, considering P<0.05 as statistically significant. Analyses were performed using STATA 14.0 (StataCorp, College Station, TX).
Results
Baseline Clinical Characteristics
We included 537 patients (n=153 BRS; n=384 DES) who underwent 554 CTO PCI. Clinical characteristics of the study population are reported in Table 1 . Notably, BRS patients were younger (60.0±9.3 versus 63.6±10.3 years; P<0.0001) and with lower prevalence of previous myocardial infarction, PCI, coronary artery bypass graft, peripheral arterial disease, transient ischemic attack/stroke, and chronic kidney disease. However, no differences were observed with regard to sex, diabetes mellitus, left ventricular ejection fraction, or indication of CTO PCI.
Baseline Angiographic Characteristics
In the overall population, mean SYNTAX score and J-CTO score were 18.6±8.8 and 1.43±1.16, respectively, with no differences between groups (Table 2) . However, BRS patients underwent more frequently CTO PCI on the left anterior descending (46.4%), whereas DES patients were treated more often on the right coronary artery (45.8%; P=0.01). BRS patients had a lower incidence of in-stent CTO PCI (6.5% versus 12.5%; P=0.04) and larger RVD. In addition, an RVD <2.5 mm was observed less frequently in BRS patients (9.9% versus 22.0%; P=0.002). Total lesion length and CTO length were lower in BRS patients.
Procedural Characteristics
The retrograde approach and dissection/reentry techniques were used twice more frequently before DES implantation (Table 3) . BRS-treated patients received larger stents that were postdilated more frequently (90.8% versus 78.6%; P=0.001) and with larger balloons. Total stent/scaffold length was similar between the 2 groups. BRS patients had a >3-fold higher use of intravascular ultrasound (IVUS) or optical coherence tomography (OCT): 68.6% versus 20.8% (P<0.0001). Variables are expressed as mean±SD, or n (%), as appropriate. BRS indicates bioresorbable scaffolds; CTO, chronic total occlusion; DES, drug-eluting stent; eGFR, estimated glomerular filtration rate; and PCI, percutaneous coronary intervention. BRS vs DES for CTO PCI Post-PCI quantitative coronary analysis data did not show angiographically relevant differences between groups.
Although contrast volume and fluoroscopy time were similar, BRS procedures were longer. The incidence of procedural complications was low (1.9%) and similar between groups. These included the following: n=6 perforations (one required covered stent implantation, another induced tamponade requiring pericardiocentesis), n=1 contrast-induced nephropathy, and n=2 femoral hematomas in DES; and n=1 femoral hematoma in BRS.
Technical success was 99.3% and 97.1% in BRS and DES patients, respectively (P=0.12); in the DES group, failure was because of final Thrombolysis In Myocardial Infarction flow <3 in all cases (n=11), whereas the only case of BRS failure was because of severe residual disease not amenable to revascularization distal to the scaffold. No case of bailout DES implantation after failed BRS delivery was observed. Procedural success was 99.3% and 96.6% (P=0.07): this difference with regard to technical success was driven by 1 case of stent thrombosis 3 days after PCI (treated with balloon angioplasty) and 1 case of tamponade requiring pericardiocentesis in the DES group. The residual SYNTAX score was low in both groups (1.5±3.7 and 3.0±5.8; P<0.0001). Finally, BRS patients were more often prescribed prasugrel or ticagrelor (60.8% versus 34.1%; P<0.0001).
Unadjusted Analysis of Clinical Outcomes on Follow-Up
Follow-up was available for n=514 patients (95.7%). Median follow-up was 703 (interquartile range 426-989) days. There were no significant differences in the unadjusted rates of events between the 2 groups (Table 4 By IPTW-adjusted Cox regression analysis (Table 4) , there were no significant differences in TVF (adjusted HR, 1.54; 95% Figure 5 shows the adjusted Kaplan-Meier curves for survival free from TVF and ID-TLR. In addition, there was no significant interaction between treatment type and use of postdilatation (P interaction =0.27), use of dissection/reentry techniques (P interaction =0.41), and use of IVUS/OCT (P interaction =0.93). Our findings were consistent in a sensitivity analysis by sequential exclusion of each enrolling site (Table II in the Data Supplement), with no apparent heterogeneity across centers (P interaction =0.47), and when tail-trimming of the propensity score was performed (data not shown).
By doubly robust IPTW-adjusted Cox regression (Table  III in the Data Supplement) , adding clinical, angiographic, and procedural variables separately to the models, there were still no significant differences in outcomes between groups.
However, when these 3 categories of variables were simultaneously added to the model, there was an increase in the risk of TVF and ID-TLR with BRS. In particular, by augmenting IPTW-adjusted Cox regression with age, SYNTAX score, J-CTO score, RVD, and use of IVUS/OCT, BRS use was associated with a trend toward higher ID-TLR (adjusted HR, 3.45; 95% CI, 0.87-13.66; P=0.08).
Discussion
The main findings of our study are as follows: (1) CTO PCI with BRS, performed by experienced operators and in selected lesions, has a high success rate, with low incidence of complications and acceptable clinical outcomes at long-term followup; (2) on adjusted analysis, the primary end point of TVF was comparable between BRS-and DES-treated subjects; (3) 1,2 To the best of our knowledge, no randomized trial or propensityadjusted comparison has been published evaluating the use of BRS versus DES in complex lesion anatomies such as CTO. To date, the safety and feasibility of BRS in CTO has mostly been assessed in single-center registries, limited by small sample sizes and the lack of a control arm. Vaquerizo et al 8 studied 35 patients who underwent successful CTO PCI with Absorb, using IVUS and OCT guidance. J-CTO score was ≥2 in 26%. Mean scaffold length was 52.5±23.0 mm. Multidetector computed tomography at 6 months showed 2 cases of asymptomatic scaffold restenosis. At 12 months, no scaffold thrombosis or TVF were reported. Ojeda et al 5 conducted a similar study (n=42). J-CTO score was ≥2 in 46%. Mean scaffold length was 43±21 mm. Technical success was achieved in 98%. Sixmonth multidetector computed tomographic follow-up showed 2 reocclusions and a focal restenosis. After 13±5 months, 2 cases (4.8%) of repeat revascularizations were observed. Wiebe et al 6 studied 23 CTO patients who underwent successful Absorb-based revascularization. Mean J-CTO score was 1.7±1.0. Mean scaffold length was 64.8±24.2 mm. During a median follow-up of 108 days, 1 case of early BRS thrombosis was observed. The registry by La Manna et al 7 was to date the only study providing a comparison between BRS and DES for CTO PCI. They compared 32 patients treated with Absorb with 54 historical controls who had undergone CTO PCI with second-generation DES in the 2 years before the introduction of BRS at their institution. Baseline characteristics were similar between the 2 groups, with the exception of a larger mean RVD in the BRS group, similar to our study. Technical success was less likely to be achieved in the BRS group (78.1% versus 96.3%; P=0.012). No follow-up data were provided.
Our study is an international multicenter registry involving 5 institutions and several experienced operators in 3 countries, with a much larger sample size. In addition, in our study, patients undergoing CTO PCI with BRS were compared with those receiving second-generation DES using strong statistical adjustment techniques and evaluating longterm follow-up.
Our results indicate that BRS-based percutaneous revascularization of CTO is feasible. We observed technical and procedural success rates of 99.3%, which were similar to those of DES. Quantitative coronary analysis of BRS-treated lesions showed encouraging data. This was achieved using Results reported as number of events (%), HR, and 95% CI. BRS indicates bioresorbable scaffolds; CI, confidence interval; DES, drug-eluting stent; HR, hazard ratio; and IPTW, inverse probability of treatment weight.
*Generated with univariate Cox regression analysis. †Generated with Cox regression modeling after IPTW adjustment stratified by center identifier. IVUS/OCT guidance and postdilatation in the majority of cases, as recommended by expert consensus recommendations, 10 which, however, further increased the duration of these already long procedures.
In unadjusted analyses, BRS exhibited similar clinical outcomes on long-term follow-up compared with DES (Table 4 ; Figure 3 ). These results were comparable with those reported for metallic everolimus-eluting stent in the 1-year follow-up of the EXPERT-CTO trial (Evaluation of the Xience Prime LL and Xience Nano Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions; ID-TLR: DES 4.1% and BRS 4.0% in our study, metallic everolimus-eluting stent 6.3% in EXPERT-CTO). 16 Our primary adjusted analysis did not show differences between BRS and DES with regard to TVF. The apparent similar performance of BRS and DES in CTO was likely because of the utilization of the former in less challenging clinical and angiographic scenarios. In particular, BRS patients were younger, had less cardiovascular comorbidities, less complex lesions, and more favorable procedural characteristics.
However, a trend toward higher adjusted risk of ID-TLR with BRS was observed. The fact that our findings did not reach statistical significance might be explained by the relatively small sample size of our cohort. In addition, in doubly robust IPTW-adjusted Cox regression analysis, including clinical and angiographic confounders, as well as key procedural variables (namely, use of intravascular imaging), statistical significance was achieved, possibly suggesting a higher risk of TVF with BRS (driven by ID-TLR). However, currently this observation should be considered as hypothesis-generating only, until randomized data become available.
These findings might have several explanations. First, it must be taken into account that the BRS studied in our registry (Absorb) is a first-generation device, which was compared with several second-generation DES. Absorb features much thicker struts compared with currently used DES (156 μm versus 80-100 μm). 17 This characteristic has been associated with rheological disturbances that might increase the risk of scaffold thrombosis and restenosis. 18, 19 A recent meta-analysis of 6 randomized controlled trials (n=3738) indicated that Absorb is associated with higher risk of scaffold thrombosis compared . Standardized mean differences (SMDs) of the covariates used for propensity score modeling before and after inverse probability of treatment weight (IPTW) adjustment. After adjustment, all covariates showed SMDs within the 10% cutoff (red vertical lines), except chronic kidney disease (−12.8%). CABG indicates coronary artery bypass graft; CTO, chronic total occlusion; J, Japan; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; and SYNTAX, Synergy Between PCI With Taxus and Cardiac Surgery. BRS vs DES for CTO PCI with second-generation metallic everolimus-eluting stent. 20 Only 3 cases of stent/scaffold thrombosis were observed in our cohort, with no difference between BRS and DES, which was probably because of the relatively small sample size of our study and the low incidence of this complication, as well as the meticulous work done by our expert operators (in particular, high rate of postdilatation and use of intravascular imaging). In addition, in our study, BRS implantation was usually avoided in small vessels, where DES were preferred, so that the risk of scaffold thrombosis might have been reduced to a great extent. Indeed, the risk of BRS thrombosis is exponentially increased when these devices are implanted in small vessels. 21 Taken together, these observations are consistent with the fact that, when doubly robust Cox regression analysis was performed adjusting for key angiographic and procedural variables (RVD and use of IVUS/OCT), differences in TVF became significant (driven by higher ID-TLR). Therefore, strict adherence to BRS implantation guidelines 10 and avoidance of BRS use in small vessels are recommended, to minimize the risk of adverse events on follow-up in this challenging lesion subset. Figure 6 summarizes our recommendations on device choice and BRS implantation technique in CTO PCI.
Regarding the low rate of ID-TLR in our series, it must be considered that the development of restenosis (both occlusive and nonocclusive) might be underdiagnosed after CTO PCI compared with non-CTO interventions. In the studies by Ojeda et al 5 and Vaquerizo et al, 8 where multidetector computed tomography was routinely performed 6 months after CTO PCI with BRS, asymptomatic BRS restenosis/reocclusion was detected in 2.4% and 5.7% of patients, respectively. Therefore, the true incidence of BRS restenosis/reocclusion might be underestimated in patients treated with CTO PCI.
Finally, it is known that chronically underperfused vessels undergo negative remodeling, which is slowly (6-12 months) reversed after successful recanalization. 22 In such setting, vessel healing after stenting/scaffolding might be delayed in CTO compared with non-CTO lesions. Therefore, because BRS maintain radial support for 3 to 6 months after implantation and subsequently disappear in ≈24 months, 17 such time frame could be too short for adequate vessel healing to be completed, and hence restenosis/reocclusion could relapse.
The present study has several limitations. First, our study is not a randomized controlled trial. Despite robust statistical analyses, we can not exclude that residual confounders might still be present. Second, sample size and observed event rates were relatively small, thereby increasing the likelihood of type 2 error for the detection of significant differences between treatment groups. However, follow-up was longer than currently available (1-year) data for the Absorb II, Absorb III, Absorb China, and Absorb trials. [1] [2] [3] [4] Nevertheless, longer-term follow-up is warranted to confirm our results and to avoid the risk of missing a late catch-up phenomenon. Finally, several second-generation DES were used in our cohort, and multiple crossing techniques, devices, and invasive imaging protocols were used. Therefore, key procedural confounders might have substantially influenced our treatment effect estimates. Nevertheless, the real-world, multicenter, international nature of our study also confers significant external validity to our findings.
Conclusions
In our experience, CTO PCI with BRS in selected patients and lesions was clinically feasible and yielded acceptable longterm clinical outcomes. Our main analysis indicated that the Figure 6 . Recommendations on device choice and bioresorbable scaffold implantation technique in chronic total occlusion percutaneous coronary intervention. *Consider drug-eluting stents in patients with comorbidities associated with aggressive coronary artery disease (eg, previous coronary artery bypass graft, advanced chronic kidney disease). These recommendations are based on data from the present study, authors' experience, and literature. 10 BAR indicates balloon-to-artery ratio; CTO, chronic total occlusion; DAPT, dual antiplatelet therapy; IVUS, intravascular ultrasound; and OCT, optical coherence tomography. BRS vs DES for CTO PCI adjusted risk of long-term TVF was similar between BRS and DES. Secondary analyses suggested a signal toward a higher incidence of ID-TLR with BRS, which, however, must be considered as hypothesis-generating only. Larger studies, with longer follow-up, and possibly a randomized controlled trial, implementing systematic use of optimal BRS implantation techniques, should confirm these findings and shed further light on the role of BRS in CTO PCI.
